The estimated Net Worth of Mark K. White is at least $482 millier dollars as of 12 October 2021. Mr. White owns over 5,000 units of Annovis Bio stock worth over $481,999 and over the last 3 years he sold ANVS stock worth over $0. In addition, he makes $0 as Board Member at Annovis Bio.
Sign up
Mr. White ANVS stock SEC Form 4 insiders trading
Mark has made over 1 trades of the Annovis Bio stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of ANVS stock worth $137,000 on 12 October 2021.
The largest trade he's ever made was buying 5,000 units of Annovis Bio stock on 12 October 2021 worth over $137,000. On average, Mark trades about 714 units every 0 days since 2021. As of 12 October 2021 he still owns at least 56,177 units of Annovis Bio stock.
You can see the complete history of Mr. White stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark White biography
Mark White serves as Board Member of the Company. Mr. White is a biopharmaceutical executive with global marketing, business development and sales experience. Currently, Mark is an independent consultant and a member of Robin Hood Ventures, a Philadelphia based angel investor group. Previously, Mark held senior level roles at Pfizer in marketing and commercial development, where he led the successful global launches of Inspira, Revatio, Lyrica and Xeljanz. In his last position, he was Vice President Worldwide Marketing, with global responsibility for new product development and in-line marketing for Pfizer’s Inflammation Therapeutic Area.
What's Mark White's mailing address?
Mark's mailing address filed with the SEC is C/O ANNOVIS BIO, INC., 101 LINDENWOOD DR, SUITE 225, MALVERN, PA, 19355.
Insiders trading at Annovis Bio
Over the last 5 years, insiders at Annovis Bio have traded over $0 worth of Annovis Bio stock and bought 24,481 units worth $662,591 . The most active insiders traders include Michael B Hoffman, Maria Luisa Maccecchini et Jeffrey Brian Mc Groarty. On average, Annovis Bio executives and independent directors trade stock every 138 days with the average trade being worth of $158,018. The most recent stock trade was executed by Maria Luisa Maccecchini on 6 February 2023, trading 52,755 units of ANVS stock currently worth $7,386.
What does Annovis Bio do?
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.
What does Annovis Bio's logo look like?
Complete history of Mr. White stock trades at Annovis Bio
Annovis Bio executives and stock owners
Annovis Bio executives and other stock owners filed with the SEC include:
-
Mark White,
Board Member -
Robert Whelan,
Board Member -
Claudine Bruck,
Board Member -
Maria Maccecchini,
Executive Board Member -
Michael Hoffman,
Chairman of the Board -
Reid Mc Carthy,
Director -
Jeffrey Brian Mc Groarty,
Chief Financial Officer -
Henry Iii Hagopian,
Chief Financial Officer